Summit Therapeutics (SMMT) Free Cash Flow (2017 - 2026)

Summit Therapeutics (SMMT) has reported Free Cash Flow for 10 consecutive years, with -$141.3 million the latest figure, recorded in Q2 2026.

• Quarterly Free Cash Flow fell 104.85% year-over-year to -$141.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$456.7 million (down 114.26% YoY) and the FY2025 annual result came in at -$323.6 million, down 127.49% from the prior year.
• Free Cash Flow retreated to -$141.3 million in Q2 2026 per SMMT's latest filing, from -$123.3 million in the prior quarter.
• Over the last five years, Free Cash Flow for SMMT reached as high as $5.2 million in Q4 2022 and fell as low as -$141.3 million in Q2 2026.
• A 5-year average of -$47.2 million and a median of -$29.8 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow surged 155.93% — and 2023, when it sank 474.18%.
• Year by year, Free Cash Flow stood at $5.2 million in 2022, then plunged by 474.18% to -$19.5 million in 2023, then tumbled by 163.44% to -$51.3 million in 2024, then sank by 91.28% to -$98.1 million in 2025, then tumbled by 44.13% to -$141.3 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$141.3 million, -$123.3 million, and -$98.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.